NVCR

Neutral

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48

H.C. Wainwright has reiterated its Buy rating for Novocure (NVCR.US) but has adjusted its target price downwards to $48. This decision reflects the fi...

Moomoo 8 hours ago 0

Neutral

NovoCure Unifies Clinical And Innovation Roles As Market Discounts Persist

NovoCure (NasdaqGS:NVCR) has combined its Chief Medical Officer and Chief Innovation Officer roles, appointing Uri Weinberg to both positions. This mo...

Simply Wall Street 2 weeks ago 0